Abstract
Background Mycobacterium tuberculosis (Mtb) infection is inferred from positive results of T-cell immune conversion assays measuring Mtb-specific interferon gamma production or tuberculin skin test (TST) reactivity. Certain exposed individuals do not display T-cell immune conversion in these assays and do not develop TB. Here we report a hitherto unknown form of this phenotype: HIV-1-positive persistently TB, tuberculin and IGRA negative (HITTIN).
Methods A community-based case-control design was used to systematically screen and identify adults living with HIV (HIV+), aged 35-60 years, who met stringent study criteria, and then longitudinally followed up for repeat IGRA and TST testing. Participants had no history of TB despite living in TB hyper-endemic environments in Cape Town, South Africa with a provincial incidence of 681/100,000. Mtb-specific antibodies were measured using ELISA and Luminex.
Findings We identified 48/286 (17%) individuals who tested persistently negative for Mtb-specific T-cell immunoreactivity (three negative Quantiferon results and one TST = 0mm) over 206±154 days on average. Of these, 97·2% had documented CD4 counts<200 prior to antiretroviral therapy (ART). They had received ART for 7·0±3·0 years with a latest CD4 count of 505·8±191·4 cells/mm3. All HITTIN sent for further antibody testing (n=38) displayed Mtb-specific antibody titres.
Interpretation Immune reconstituted HIV+ persons can be persistently non-immunoreactive to Mtb, yet develop species-specific antibody responses. Exposure is evidenced by Mtb-specific antibody titres. Our identification of HIV+ individuals displaying a persisting lack of response to TST and IGRA T-cell immune conversion paves the way for future studies to investigate this phenotype in the context of HIV-infection that so far have received only scant attention.
Funding Funding provided by National Institutes of Health [1R01AI124349-01].
Evidence before this study The majority of individuals who are exposed to Mycobacterium tuberculosis (Mtb) appear to have natural immunity against developing tuberculosis (TB). A subset of these individuals may clear or control Mtb without developing a classical T-cell immune response as measured by a tuberculin skin test (TST) or IGRA. While the gold standard for TB diagnosis is culturing Mtb from a specimen, there is no direct test to prove current Mtb infection. Hence, infection needs to be inferred from tests that measure Mtb T-cell immunoreactivity. Once Mtb is inhaled, pulmonary innate immune cells, so-called alveolar macrophages, are the first to make contact with the bacilli. Mtb-infected alveolar macrophages traverse from the alveoli to the lung interstitium where Mtb is transferred to inflammatory macrophages that present the bacilli to T-cells and initiate the adaptive immune response, including the generation of memory T-cells. The current Mtb T-cell immunoreactivity tests indicate infection if positive. A major caveat with these tests is an inability to distinguish between a current infection or a persistent immune response after a previous infection that was cleared. In addition it is important to clarify that persisting negative immunoreactivity does not simply imply that individuals are not infected. They could have had previous immunoreactivity which has reverted, could not have been exposed to Mtb or they were exposed but cleared Mtb without a classical IFN-γ T-cell immunoreactive response. The latter is a novel concept and previous studies in HIV-negative subjects have focused on this resistance to ‘infection’- or to be more precise failure of IFN-γ T-cell and TST immune conversion to Mtb. However, these studies found Mtb-specific antibodies in their HIV-negative ‘resister’ subjects. The presence of especially IgG antibodies confirmed and indicated long term exposure to Mtb and pointed to current or cleared infection. T-cell responses are required for antigen-specific B-cells to release class-switched IgG. Since these individuals test persistently negative for TST and IFN-γ T-cell immunoreactivity, innate and alternative adaptive IFN-γ independent T-cell responses should be investigated. This is a developing field and as research emerges, it is increasingly important to clearly characterize and define the TB resistance phenotype.
Added value of this study HIV-positive (HIV+) persons are at increased risk of infection with Mtb and rapid progression to tuberculosis making the phenotype we describe here especially important in this population segment. However, there is a major lack of data in HIV+ persons describing persisting lack of response to TST and Mtb IFN-γ T-cell immune conversion. Here we show that this phenotype can be identified in immune-reconstituted HIV+ persons. We describe the recruitment and define this conversion resistance phenotype as HIV-1-positive persistently TB, tuberculin and IGRA negative (HITTIN). The presence of specific antibodies confirms exposure to Mtb. Our study suggests possible innate mechanisms and non-classical adaptive mechanisms that subvert early stages of tuberculosis pathogenesis in a substantial proportion of HIV-infected patients. Harnessing such TST and IFN-γ T- cell independent mechanisms of resistance is of particular interest for prevention of tuberculosis in the HIV+ population.
Implications of all the available evidence Understanding the mechanisms of resistance will enable us to develop TB prevention and treatment modalities.
Competing Interest Statement
Declaration of Interests Dr Möller reports grants from National Institutes of Health, during the conduct of the study. Dr. Schurr reports to be the PI on NIH 1R01AI124349. The study was also partly funded by the Canadian Institutes of Health Research (CIHR) through grant FDN-143332 for which Dr. Schurr is the PI. Dr Kroon reports grants from National Institutes of Health, other from European and Developing Countries Clinical Trials Partnership, other from South African Medical Research Council during the conduct of the study. Dr Alter reports other from Seromyx Systems Inc outside the submitted work. In addition, Dr. Alter has a patent Systems Serology pending to Galit Alter. Dr. Wilkinson reports grants from Wellcome, grants from UK Research and Innovation, grants from Cancer Research UK, grants from National Institutes of Health, during the conduct of the study. Dr Walzl, Dr Hoal, Prof Kinnear, Dr Boolay, Dr Fischinger, Dr Orlova, Dr Jacobs and Ms Shin have nothing to disclose.
Funding Statement
This work was supported by the National Institutes of Health [1R01AI124349-01]. This research was partially funded by the South African government through the South African Medical Research Council (SAMRC) and supported by the National Research Foundation of South Africa. The content is solely the responsibility of the authors and does not necessarily represent the official views of the SAMRC. ES is supported by a Foundation grant from the Canadian Institutes of Health Research [FDN-143332]. RJW receives funding from the Francis Crick Institute, which is supported by United Kingdom Research and Innovation [FC0010218], Cancer Research UK [FC0010218], and Wellcome [FC0010218]. RJW is also supported by Wellcome [104803, 203135] and the National Institutes of Health [U19AI111276]. EEK is supported through funding by the SAMRC through its Division of Research Capacity Development under the Clinician Researcher Development PHD Scholarship Programme. EEK is also supported by a Career Development Fellowship [TMA2018CDF-2353-NeutroTB] awarded by The European and Developing Countries Clinical Trials Partnership.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Ethics Committee (HREC) of Stellenbosch University [N16/03/033 and N16/03/033A] and the Faculty of Health Sciences Human Research Ethics Committee of the University of Cape Town [HREC 755/2016 and 702/2017]. Additional approval was obtained from the City of Cape Town and Western Cape government for access to the relevant clinics.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 1 and Table 2 updated and revised. Text added in introduction to clarify hypothesis. Manuscript revised to clarify the HITTIN phenotype.
Data Availability
The data that support the findings of this study are available from the corresponding author, Dr. Möller, upon reasonable request.
